Clinical observation on Aidi injection combined with GP chemotherapy in treating advanced non-small cell lung cancer

Objective To evaluate the therapeutic effectiveness and KPS(scores of quality of life) and adverse reaction of Aidi injection combined with GP regimen in treating advanced non-small cell lung cancer(NSCLC).Methods 160 cases of advanced NSCLC were divided into two groups randomly: 90 cases(combined group) were treated with combined therapy of Aidi injection with GP,while the other 70 cases(control group) treated with only chemotherapy.Results There was obvious difference in clinical benefit rates between the two groups.The clinical benefit rate(CR+PR+SD) was 86.7% in combined group and 71.4% in control group,with significant difference(P=0.039).Improving rate of KPS was 64.4%(58/90)in the combined group,while in the other group was 45.7%(32/70),P=0.01.The nausea and vomiting rates of Aidi plus GP was obviously decreased compared with control group.Rate of lenkopenia was 28.9%(26/90) in the combined group,and 44.3%(31/70) in the other group,P=0.03.The thrombocytopenia was 13.3%(12/90) in the combined group,and 32.9%(23/70) in the other group,P=0.03.Hepatic function and renal function toxicity has no statistically significant difference(P=0.03).Conclusion The efficacy of Aidi injection combined with GP regimen is better than GP regimen alone,and score of quality of life of Aidi injection combined with GP regimen is better than GP regimen alone,the side effects are milder in combined group than in control group.